Volume 5, Issue 1, Spring 2026

Articles

• 

  Current Management of Relapsed or Refractory Classic Hodgkin Lymphoma in Canada

  Colin Stewart, MD, Robert Puckrin, MD

  5–14

  • PDF (en)
• 

  Approach to Patients with Acute Myeloid Leukemia in First Relapse: A Practical Guide for Canadian Hematologists

  Cristiano Machado de Freitas, MD, Guillaume Richard-Carpentier, MD

  16–23

  • PDF (en)
• 

  Upfront Therapy for Non‑transplantable Multiple Myeloma in 2026: Decision‑making in an Increasingly Complex Therapeutic Landscape

  Rina Latscha, MD, Sita Bhella, MD

  24–35

  • PDF (en)
• 

  Is Continuous Therapy Becoming Finite? The Evolving Landscape of CLL Treatment in 2026

  Stephanie Craig, MD, Shannon Murphy, MD

  37–43

  • PDF (en)
• 

  High-Risk Multiple Myeloma in 2026: Evolving Definitions and Therapeutic Options

  Andrew J. Cowan, MD, Kevin Song, MD, Florian Kuchenbauer, MD, Christopher P. Venner, MD

  45–53

  • PDF (en)